Centiva Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

Centiva Capital’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-15,000	Closed	-$1.35M	–	859
2020 Q1	$1.35M	Buy	+15,000	New	+$1.47M	0.06%	177

Other funds holding ALXN

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Centiva Capital's ALXN Position: Q3 2021 in Review

Centiva Capital sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 46,039 shares — an estimated $8.46M sold.

Centiva Capital first reported a position in ALXN in Q3 2019 and held it in 6 quarters. The position peaked at $8.75M in Q1 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Centiva Capital reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Centiva Capital sold 46,039 Alexion Pharmaceuticals shares in Q3 2021, an estimated $8.46M.
Centiva Capital first reported a position in Alexion Pharmaceuticals in Q3 2019 and held it in 6 quarters.
Centiva Capital's Alexion Pharmaceuticals position peaked at $8.75M in Q1 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Centiva Capital's 13F filing for Q3 2021, filed 15 Nov 2021.